By Paul Ziobro
Cyclacel Pharmaceuticals is looking at various strategic alternatives and cutting costs as it seeks to preserve cash.
The alternatives include a potential transaction with investor David Lazar of Activist Investing LLC, which would be subject to the consent of an existing securityholder, the company said Thursday.
The company's board has directed management to reduce operating costs while it explores any alternatives.
Based in Berkley Heights, N.J., Cyclacel is a biopharmaceutical company developing cancer medicines.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
December 05, 2024 16:50 ET (21:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.